P21
A synthetic CNTF-derived neurotrophic peptide studied in rodents for driving hippocampal neurogenesis, BDNF expression, and memory while sparing the cachexia caused by full-length CNTF.
P21 (P021) is a small synthetic peptide derived from the neurotrophic activity domain of ciliary neurotrophic factor (CNTF), engineered by Khalid Iqbal's group at the New York State Institute for Basic Research to reproduce CNTF's pro-neurogenic and BDNF-inducing effects without the JAK/STAT3-driven peripheral cachexia and muscle wasting that limited native CNTF. In transgenic Alzheimer's and aging rodent models it has increased hippocampal neurogenesis, upregulated BDNF and other neurotrophins, improved learning and memory, and reduced amyloid-beta and tau pathology. All published evidence is preclinical (animal); no human clinical trials have been registered or completed, and it is sold strictly as a research-use-only compound. Note: some vendors apply the 'P21' label to an unrelated Selank-derived cyclic dipeptide (Cyclo-Pro-Gly, MW 154), so buyers should confirm the exact compound and sequence.
Class
Synthetic CNTF-derived neurotrophic peptide (CNTF mimetic/fragment)
Half-life
Unknown in humans; no published pharmacokinetic data
Routes
Intranasal (dominant), Subcutaneous (uncommon), Oral (poorly absorbed)
Category
Cognitive & Nootropic
Researched benefits
What it's studied for
Hippocampal neurogenesis
In adult and aged mice, peripheral or central P21 increased the birth and maturation of new neurons in the dentate gyrus of the hippocampus, the region most tied to learning and memory. This neurogenic effect is the compound's signature action and develops over weeks.
BDNF and neurotrophin upregulation
P21 elevates brain-derived neurotrophic factor (BDNF) and other neurotrophins in the hippocampus and cortex, reproducing a key downstream effect of CNTF signaling that supports synaptic maintenance and plasticity.
Improved learning and memory
Rodent studies reported enhanced short-term and spatial reference memory (Morris water maze, novel object recognition) in normal adult and aged animals as well as in disease models, linked to the neurogenic and neurotrophic effects.
Reduced Alzheimer's-type pathology
In 3xTg-AD and APP/PS1 transgenic mice, P021 lowered amyloid-beta burden and tau hyperphosphorylation, rescued synaptic deficits, and (with early continuous treatment) reduced neurodegeneration and mortality over long follow-up.
Synaptic plasticity support
Beyond generating new neurons, P21 promoted maturation of newly born neurons and improved markers of synaptic density and plasticity, consistent with a neurotrophic mode of action via MAPK/ERK and PI3K/Akt signaling.
CNS-selective CNTF activity
P21 was specifically designed to engage the neurogenic/BDNF-inducing arm of CNTF while avoiding the peripheral JAK/STAT3 activation that causes cachexia and muscle wasting with full-length CNTF, giving a cleaner theoretical safety profile.
Mechanism
How it works
P21 is derived from a defined active region of ciliary neurotrophic factor (CNTF), a neuroprotective cytokine that promotes neuron survival, BDNF production, and hippocampal plasticity. Full-length CNTF failed as a therapeutic largely because systemic administration activates peripheral CNTF receptors and JAK/STAT3 signaling, producing cachexia, weight loss, and immune responses. P21 was engineered to preserve the pro-neurogenic and BDNF-inducing effects of CNTF while avoiding this peripheral toxicity, with adamantane incorporation intended to improve metabolic stability and CNS penetrance.
Mechanistically, P21 is proposed to upregulate BDNF and other neurotrophic factors through MAPK/ERK signaling, with modulation of the PI3K/Akt pathway also reported. The net downstream effect is stimulation of adult neurogenesis in the dentate gyrus, enhanced maturation of newly born neurons, and support of synaptic plasticity. In neurodegeneration models these same pathways are associated with reduced tau hyperphosphorylation and lower amyloid-beta accumulation.
Because the intended target is the central nervous system, intranasal delivery is the dominant experimental route, exploiting olfactory and trigeminal pathways to bypass the blood-brain barrier that limits systemic peptide delivery to the brain. Subcutaneous and oral routes are used less often because they provide poor brain penetration or are degraded in the gastrointestinal tract.
Important caveat: the 'P21' name is applied inconsistently in the vendor market. The compound described here is the CNTF-derived neurotrophic peptide (P021) from the Iqbal laboratory. A separate, chemically unrelated compound — a Selank-derived cyclic dipeptide, Cyclo(L-prolyl-glycine), MW 154 — is also sometimes sold as 'P-21' and acts through GABAergic and anti-inflammatory mechanisms. Confirming the exact sequence and identity with the vendor is essential.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Supplied as lyophilized powder, typically 5 mg or 10 mg per vial. For the dominant intranasal route, reconstitute with sterile or bacteriostatic saline (0.9% NaCl, isotonic with nasal mucosa) rather than plain water to minimize irritation and extend multi-dose shelf life. A standard preparation is 5 mL of saline into a 10 mg vial for 2 mg/mL; a nasal spray delivering ~0.1 mL per actuation then provides ~200 mcg per spray (500 mcg ~ 2-3 sprays, 1000 mcg = 5 sprays, 2000 mcg = 10 sprays). Inject diluent down the vial wall, swirl gently, inspect for clarity, transfer to a clean nasal spray bottle, and refrigerate; reconstituted solution in bacteriostatic saline is typically stable ~4-8 weeks. Discard for cloudiness, discoloration, or particulates.
Beginner
- Dose
- 500 mcg
- Frequency
- Once daily
- Timing
- Morning (to avoid sleep interference)
- Duration
- 4-6 weeks, then reassess
- Route
- Intranasal
Conservative starting point drawn from community convention, not clinical validation. Use P21 alone (no stacking) so effects can be attributed. Track cognition, mood, sleep, and any nasal symptoms.
Intermediate
- Dose
- 1000 mcg/day (or 500 mcg twice daily)
- Frequency
- Once or twice daily
- Timing
- Morning, or split morning/midday
- Duration
- 8-12 weeks on, 4-8 weeks washout
- Route
- Intranasal
For users who tolerated beginner cycles. Divided dosing is used on the theory of steadier CNS exposure, though no PK data support it. Often combined with baseline/follow-up cognitive and lab monitoring.
Advanced
- Dose
- 1500-2000 mcg/day
- Frequency
- Once daily or divided (up to 3x)
- Timing
- Morning-weighted
- Duration
- 12-24 weeks on, extended washout
- Route
- Intranasal
No clinical evidence supports advanced doses over intermediate; marginal benefit likely plateaus. Advanced users sometimes integrate P21 into broader nootropic/longevity stacks, accepting loss of attribution and compounded unknowns.
- Published rodent-derived 'research doses' cited by vendors are far lower (~10-50 mcg intranasal); the 500-2000 mcg human self-experiment range is extrapolated via allometric scaling and community reports, with no clinical validation.
- Intranasal is preferred for this CNS-targeted peptide; oral administration is considered ineffective (GI degradation) and subcutaneous provides poor brain penetration.
- Neurogenic effects manifest over weeks — a meaningful evaluation requires a full 4-12 week cycle with before/after cognitive and mood assessment, not a few days of dosing.
- Cycle structure is typically 4-24 weeks on followed by 4-12 weeks washout, 2-3 cycles per year; continuous year-round dosing is not evidence-supported.
- Body-weight adjustment is generally not made; absolute doses are used regardless of body mass. Store lyophilized powder frozen; storage in the freezer preserves potency 1-2 years.
- Vendor quality and sequence verification (LC-MS identity, HPLC purity) matter especially for P21 because reported sequences vary across preparations and the compound name is applied to more than one molecule.
Evidence
Research & clinical studies (4)
Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice
Peripheral administration of the neurotrophic peptide P21 (Ac-DGGLAG-NH2) enhanced short-term and spatial reference memory in adult mice and promoted neurogenesis and maturation of newly born neurons in the dentate gyrus.
PMID 20600002Prevention of Amyloid-beta and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound
In 3xTg-AD mice, early continuous P021 treatment begun before overt pathology prevented neurodegeneration, reduced amyloid-beta and tau accumulation, rescued episodic memory, and markedly reduced mortality over 18 months.
PMID 28387677Chohan et al. — CNTF-derived neurotrophic peptide characterization (cited by vendor monographs)
Reported increased hippocampal neurogenesis and neurotrophin expression with a CNTF-derived peptide, cited as a foundational P21 characterization study.
Kazim et al. — P021 in Alzheimer's transgenic models (cited by vendor monographs)
Reported improvements in learning/memory and reductions in AD-type pathology in 3xTg-AD and APP/PS1 mice following P021 treatment.
Combinations
Stacking & blends
P21 + Semax
Layered neurotrophic and cognitive support
Vendor interaction matrices list Semax as synergistic with P21; both act on BDNF-related neurotrophic signaling, though combining them makes single-compound attribution impossible.
P21 + NSI-189 / Dihexa
Broad pro-neurogenic / synaptogenic experimentation
Listed as compatible in community interaction data; each targets neurogenesis or synaptic growth by different mechanisms. Compounds unknowns and should be approached cautiously.
P21 advanced nootropic stack
Comprehensive CNS/neuroprotective coverage
Advanced self-experimenters combine P21 with anxiolytic (Selank), sleep-architecture (DSIP), neuroprotective (PE-22-28), and Khavinson-tradition (Pinealon) peptides, accepting that attribution and interaction risk grow substantially.
P21 + foundational supplements
Support neuronal membranes, methylation, and synaptic function
Conventional brain-health supplements with stronger evidence bases than research peptides are commonly co-used and can be continued without cycling; no validated synergy but generally good tolerability.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy and breastfeeding (absolute) — neurotrophic signaling in development is tightly regulated
- Children and adolescents (developing brain highly sensitive to neurotrophic manipulation)
- Seizure disorders/epilepsy (BDNF elevation can lower seizure threshold in some contexts)
- Active psychiatric medication use (SSRIs, SNRIs, TCAs, MAOIs, antipsychotics, lithium) without psychiatrist involvement
- Active malignancy or cancer surveillance (BDNF effects on tumors are type-dependent and uncharacterized)
- Acute/subacute stroke or traumatic brain injury (within ~6 months) without neurologist input
- Active CNS or sinus/respiratory infection (absolute for intranasal use)
- Known peptide or preservative (benzyl alcohol, parabens) hypersensitivity
- Chronic nasal/sinus conditions or bleeding disorders/anticoagulant therapy (caution for intranasal route)
No human safety, toxicity, or pharmacokinetic data exist; preclinical rodent studies have not surfaced significant toxicity at researched doses, and the mimetic design specifically aimed to avoid CNTF's cachexia and immune liabilities. The most important limitation is the absence of clinical oversight — CNS-active research peptides warrant a knowledgeable physician who can monitor for subtle mood, cognitive, or psychiatric changes. Long-term safety is entirely unknown.
FAQ
P21 — common questions
What is P21 (P021)?
It is a small synthetic peptide derived from the neurotrophic active region of ciliary neurotrophic factor (CNTF), developed by Khalid Iqbal's laboratory to reproduce CNTF's pro-neurogenic and BDNF-inducing effects in the brain without the cachexia and muscle wasting caused by full-length CNTF. It upregulates BDNF via MAPK/ERK signaling, promotes hippocampal neurogenesis, and reduces tau and amyloid pathology in preclinical models.
Has P21 been tested in humans?
No. As of 2026 there are no completed or registered human clinical trials of P21, despite strong preclinical data in Alzheimer's transgenic mouse models. It remains a preclinical, research-use-only compound, and many neurotrophic strategies that worked in mice have failed in human trials, so translation is uncertain.
Why is intranasal administration preferred?
Intranasal delivery reaches the CNS through olfactory and trigeminal nerve pathways, bypassing much of the blood-brain barrier that limits systemic peptide delivery to the brain. For a CNS-targeted peptide like P21, this theoretically produces higher brain exposure per dose than subcutaneous or oral routes, though intranasal bioavailability in humans has not been measured. Oral dosing is considered ineffective due to gastrointestinal degradation.
What doses do people use?
Self-report communities describe 500-2000 mcg intranasally per day, most commonly 500-1000 mcg, usually once daily in the morning. These figures are extrapolated from rodent studies by allometric scaling and vendor guidance and have no clinical validation; published rodent 'research doses' are far lower (~10-50 mcg).
How quickly should effects appear?
Neurogenic effects develop over weeks, not days. Any subjective effects typically emerge after 2-4 weeks of consistent dosing, so a full 4-12 week cycle with before/after cognitive and mood assessment gives more informative data than judging by feel after a few days.
Can P21 help with depression or anxiety?
Its BDNF-promoting mechanism overlaps with how antidepressants ultimately act, and some users report mood improvement, but there are no human studies of P21 in depression or anxiety. Combining it with prescription antidepressants should involve a psychiatrist because the interaction is uncharacterized; evidence-based treatments have far stronger support.
Is there more than one compound sold as 'P21'?
Yes, and this is a key point. The compound described here is the CNTF-derived neurotrophic peptide (P021). Some vendors apply 'P-21' to an unrelated Selank-derived cyclic dipeptide, Cyclo(L-prolyl-glycine) (MW ~154), which works through GABAergic and anti-inflammatory mechanisms. Confirm the exact sequence and identity with the vendor and request third-party HPLC/mass-spec verification.
Is P21 safe for long-term use?
Long-term safety in humans is unknown; the compound has not been studied beyond the preclinical stage. Chronic manipulation of neurotrophic pathways over years could have effects not apparent in short rodent studies, so a conservative cycling approach (4-12 weeks on, 4-8 weeks off) is used to limit cumulative exposure and to test whether benefits persist between cycles.
